Related Experiment Videos
Osteogenic sarcoma after orbital radiation rhabdomyosarcoma
Chee-Chew Yip1, Robert C Kersten, Timothy J McCulley
1Department of Ophthalmology, The Cincinnati Eye Institute and The University of Cincinnati College of Medicine, Barrett Center-0670, 242 Goodman Street, Cincinnati, OH 45219-2316, USA.
Ophthalmology
|October 3, 2003
Summary
Osteogenic sarcoma, a rare secondary cancer, can develop years after treating orbital rhabdomyosarcoma with radiation and chemotherapy. Lifelong monitoring is crucial for survivors.
Area of Science:
- Oncology
- Radiation Oncology
- Pediatric Oncology
Background:
- Rhabdomyosarcoma is a common pediatric malignancy.
- Orbital rhabdomyosarcoma treatment often involves radiation and chemotherapy.
- Secondary malignancies are a known risk of cancer therapy.
Observation:
- A case report details an 11-year-old male with secondary osteogenic sarcoma.
- The patient had prior treatment for contralateral orbital rhabdomyosarcoma.
- Diagnosis occurred 10 years post-treatment, presenting as maxillary and orbital swelling.
Findings:
- Biopsy confirmed osteogenic sarcoma in the maxilla and orbit.
- Despite maxillectomy and adjuvant therapy, local tumor progression was noted.
- This highlights a rare but serious long-term complication of orbital radiation.
Implications:
- Osteogenic sarcoma can manifest years after orbital rhabdomyosarcoma treatment.
- Routine lifelong surveillance is recommended for patients treated with orbital radiation.
- Early detection of secondary malignancies is critical for patient outcomes.